Cevira® (APL-1702)

About Asieris Pharmaceuticals

Founded in 2010 and publicly listed in China (688176.SH), Asieris Pharmaceuticals is a global biopharma leader in genitourinary and women's health. Its strategy integrates in-house R&D with global partnerships, supported by advanced technology platforms for drug discovery. The company has achieved significant milestones, including the approval of its first-in-class therapy Cevira® in China and the submission of a Marketing Authorization Application to the European Medicines Agency.

About Photocure

Photocure ASA, 'The Bladder Cancer Company,' is a commercial-stage biopharmaceutical firm dedicated to improving the diagnosis and management of bladder cancer through its photodynamic technology platform. Its approved product, Hexvix, enhances the accuracy of cystoscopy procedures, leading to better patient outcomes and reduced recurrence rates. The company is actively pursuing partnerships, AI integration, and new clinical data to solidify its position as a leader in urologic oncology diagnostics while maintaining a strong commitment to ESG principles.

Therapeutic Areas